Luvo Health review
Publishes an unusually complete price grid covering compounded injections, oral tablets and brand Ozempic and Zepbound, but charges you before any clinician has reviewed your intake.
Pricing last checked on Luvo Health's own site .
- Semaglutide
- $249 per 4 weeks (injection)
- Tirzepatide
- $339 per 4 weeks (injection)
- Coverage
- Multi-state
- Brand-name
- Yes
The scorecard
Luvo Health scored on our six published factors. See the methodology.
What we like
- The full price grid is public at /pricing: every medication against every commitment length, with no account or intake required
- Stocks brand Ozempic at $1,299 per four weeks and brand Zepbound at $1,399 per four weeks alongside the compounded lines
- Offers compounded semaglutide as oral tablets ($279 per four weeks) as well as injection, which most cash-pay competitors do not
- Publishes a full refund where a provider disqualifies you before the medication has been ordered
- LegitScript certification is genuine: seal ID 6440449 resolves on LegitScript's own host and the embed hard-codes www.luvohealth.com
- Also available on the same account: NAD+ Injection and Sermorelin, a separate longevity line, each starting at $27/week
The caveats
- Compounded semaglutide and tirzepatide are not FDA-approved and are not reviewed by the FDA for safety, effectiveness or quality
- Billed in four-week blocks, not calendar months, so a year costs thirteen payments rather than twelve
- Billing starts once you complete the intake form, which is before a clinician has reviewed you
- The refund window can be zero: refunds stop once medication is 'ordered', and for new patients with no video visit that is at intake submission
- Cancellation needs 72 hours notice or you are charged for another cycle, and prepaid bundle refunds are recalculated at the higher non-bundled rate
The verdict
Best for: A shopper who wants to compare compounded, oral and brand-name GLP-1 prices side by side without handing over an email address first. Publishes an unusually complete price grid covering compounded injections, oral tablets and brand Ozempic and Zepbound, but charges you before any clinician has reviewed your intake.
Ranked #340 of 539 providers we have reviewed — for comparison, read the CoreAge Rx review, our #1 pick. In the ranking it sits between Spry at #339, 62/100 above and VevaRX at #341, 61/100 below, with the BeyondMD ruling the next one down.
A grade C is a ranking, not an instruction to stop looking: the closest rivals to Luvo Health are ruled on the identical rubric, so the comparison is like for like.This ruling sits inside a bigger one: the complete ranking puts this ruling in context against every program we track. We have also ruled on it directly: CoreAge Rx vs Luvo Health goes to CoreAge Rx, 94/100 to 59/100.
Compare with other providers
The closest rulings to Luvo Health by Verdict Score — the realistic shortlist if you are weighing this one up.
- #384TeleZen MD— TeleZen MD (telezenmd.com) is a fully online telehealth practice.59/100
- #385TRT Nation— TRT Nation is a men's telehealth platform focused primarily on testosterone replacement therapy, with compounded GLP-1 weight loss as a secondary vertical.59/100
- #386NuuVim— NuuVim is a Texas-based DTC telehealth program offering compounded semaglutide and tirzepatide in both injectable and oral forms — oral access is uncommon here — plus limited brand-name Ozempic and Zepbound.59/100
- #387Actin— Actin offers compounded semaglutide with B12 for weight loss.58/100
- #388Dollar Dad Club— Men's health telehealth brand offering GLP-1 weight loss treatments.58/100
- #389FuturHealth— FuturHealth Inc. is a San Diego-based telehealth weight management brand offering brand-name Ozempic, Wegovy (injection AND oral pill), Mounjaro, Zepbound, and Foundayo (orforglipron oral pill, added58/100
Pricing, states and verification reflect Luvo Health's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on Luvo Health's site. Not medical advice; see our disclosure.